Veracyte to Launch New Afirma Xpression Atlas and Present Platform Performance Data at AACE 2018 Meeting
Multiple Abstracts Showcasing “Real-World” Performance of the Afirma Genomic Sequencing Classifier also to be Presented
“Our RNA sequencing capabilities enable us to assess thyroid nodules at
a much more granular genomic level than previously possible,” said
The following abstract will demonstrate the ability of the RNA-based Afirma Xpression Atlas to identify – from fine-needle aspiration samples – 761 DNA variants and 130 RNA fusions partners in over 500 genes that are associated with thyroid cancer:
Title: |
Detecting Expressed Variants and Fusions in RNA-Seq Data from Thyroid FNAs (Poster #1227) |
Presenter: |
Peter M. Sadow, M.D., Massachusetts General Hospital and Harvard Medical School |
Date/Time: |
Saturday, May 19, 10:00-11:00 a.m. Eastern Time |
Location: |
Hynes Convention Center, Exhibit Hall |
The following abstracts will demonstrate the next-generation Afirma GSC’s ability to identify significantly more benign thyroid nodules, as compared to the original Afirma test: | |
Title: |
Afirma GSC: Early Endocrine Surgical Practice Performance |
Presenter: |
Richard M. Harrell, M.D., Memorial Healthcare System (Poster #1200) |
Date/Time: |
Saturday, May 19, 10:00-11:00 a.m. Eastern Time |
Location: |
Hynes Convention Center, Exhibit Hall |
Title: |
Early Experience of Gene Sequencing Classifier Compared to Gene Expression Classifier (Poster #1211) |
Presenter: |
Mayumi Endo, M.D., The Ohio State University |
Date/Time: |
Saturday, May 19, 10:00-11:00 a.m. Eastern Time |
Location: |
Hynes Convention Center, Exhibit Hall |
Title: |
High Afirma GSC Benign Call-Rate and Estimated Negative Predictive Value (Poster #1229) |
Presenter: |
Sharif Ahmed, M.D., Lankenau Medical Center |
Date/Time: |
Saturday, May 19, 10:00-11:00 a.m. Eastern Time |
Location: |
Hynes Convention Center, Exhibit Hall |
Veracyte also will host the following Product Theater event: | |
Title: |
Evolving the Standard of Care—Reviewing Afirma GSC Experience and Introducing the New Xpression Atlas |
Presenters: |
Giulia C. Kennedy, Ph.D., and Richard T. Kloos, M.D., Veracyte |
Christian Nasr, M.D., Cleveland Clinic | |
Date/Time: |
Friday, May 18, 1:15-2:00 p.m. Eastern Time |
Location: |
Hynes Convention Center, Product Theater B |
For more information, please visit AACE 2018 Booth #707 or www.veracyte.com/AACE2018. |
|
About Afirma
Veracyte’s Afirma solution provides a comprehensive solution for
physicians evaluating patients with potentially cancerous thyroid
nodules. The Afirma Genomic Sequencing Classifier combines RNA
sequencing data with machine learning to identify patients with benign
thyroid nodules among those with indeterminate cytopathology results in
order to avoid unnecessary surgery and preserve the thyroid. Since the
commercial introduction of Afirma in 2011,
About Veracyte
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, our belief that our genomic tests will transform the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis; statements regarding our Afirma Xpression Atlas platform, which we plan to introduce soon; and Afirma’s ability to significantly improve patient care and reduce healthcare costs. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the benefits of our tests, the applicability of clinical results to actual outcomes; the laws and regulations applicable to our business, including potential regulation by the Food and Drug Administration or other regulatory bodies; our ability to sell our Afirma tests and successfully transition to our next-generation Afirma GSC; our ability to successfully achieve and maintain adoption of and reimbursement for our products; the amount by which use of our products are able to reduce invasive procedures and misdiagnosis, and reduce healthcare costs; the occurrence and outcomes of clinical studies; and other risks set forth in our filings with the Securities and Exchange Commission, including the risks set forth in our quarterly report on Form 10-Q for the quarter ended March 31, 2018. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180510005481/en/
Source:
Veracyte, Inc.
Media:
Tracy Morris, 650-380-4413
tracy.morris@veracyte.com
Investors:
Keith
Kennedy, 650-243-6357
Chief Financial Officer
keith@veracyte.com